Plasma levels of trefoil factors are increased in patients with advanced prostate cancer

Clinical Cancer Research

Volumn 12, Issue 3 I, 2006, Pages 807-812

  Vestergaard, Else Marie ^a   Borre, Michael ^a   Poulsen, Steen Seier ^b   Nexø, Ebba ^a   Tørring, Niels ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN A; PROSTATE SPECIFIC ANTIGEN; TREFOIL PEPTIDE; TREFOIL PEPTIDE 1; TREFOIL PEPTIDE 2; TREFOIL PEPTIDE 3; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE METASTASIS; CANCER STAGING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDY; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY;

AGED; AGED, 80 AND OVER; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PEPTIDES; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR SUPPRESSOR PROTEINS;

EID: 32944478752     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1545     Document Type: Article

References (28)

1. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 2004;172:1297-301.
2. Welsh JB, Sapinoso LM, Su AI, et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 2001;61:5974-8.
3. Dhanasekaran SM, Barrette TR, Ghosh D, et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001;412:822-6.
4. Luo J, Duggan DJ, Chen Y, et al. Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res 2001;61:4683-8.
5. Faith DA, Isaacs WB, Morgan JD, et al. Trefoil factor 3 overexpression in prostatic carcinoma: prognostic importance using tissue microarrays. Prostate 2004;61:215-27.
6. Garraway IP, Seligson D, Said J, Horvath S, Reiter RE. Trefoil factor 3 is overexpressed in human prostate cancer. Prostate 2004;61:209-14.
7. Bonkhoff H, Stein U, Welter C, Remberger K. Differential expression of the pS2 protein in the human prostate and prostate cancer: association with premalignant changes and neuroendocrine differentiation. Hum Pathol 1995;26:824-8.
8. Colombel M, Dante R, Bouvier R, et al. Differential RNA expression of the pS2 gene in the human benign and malignant prostatic tissue. J Urol 1999;162:927-30.
9. Hoffmann W, Jagla W, Wiede A. Molecular medicine of TFF-peptides: from gut to brain. Histol Histopathol 2001;16:319-34.
10. Jakowlew SB, Breathnach R, Jeltsch JM, Masiakowski P, Chambon P. Sequence of the pS2 mRNA induced by estrogen in the human breast cancer cell line MCF-7. Nucleic Acids Res 1984;12:2861-78.
11. Prud'homme JF, Fridlansky F, Le Cunff M, et al. Cloning of a gene expressed in human breast cancer and regulated by estrogen in MCF-7 cells. DNA 1985;4:11-21.
12. Jørgensen KH, Thim L, Jacobsen HE. Preparation and characterization of PSP, a new polypeptide from porcine pancreas. Diabetologia 1981;21:288.
13. Jørgensen KH, Thim L, Jacobsen HE. Pancreatic spasmolytic polypeptide (PSP): I. Preparation and initial chemical characterization of a new polypeptide from porcine pancreas. Regul Pept 1982;3:207-19.
14. Thim L, Jørgensen KH, Jorgensen KD. Pancreatic spasmolytic polypeptide (PSP): II. Radioimmunological determination of PSP in porcine tissues, plasma and pancreatic juice. Regul Pept 1982;3:221-30.
15. Suemori S, Lynch-Devaney K, Podolsky DK. Identification and characterization of rat intestinal trefoil factor: tissue- and cell-specific member of the trefoil protein family. Proc Natl Acad Sci U S A 1991;88:11017-21.
16. Podolsky DK, Lynch-Devaney K, Stow JL, et al. Identification of human intestinal trefoil factor. Goblet cell-specific expression of a peptide targeted for apical secretion. J Biol Chem 1993;268:6694-702.
17. Emami S, Rodrigues S, Rodrigue CM, et al. Trefoil factor family (TFF) peptides and cancer progression. Peptides 2004;25:885-98.
18. Taupin D, Ooi K, Yeomans N, Giraud A. Conserved expression of intestinal trefoil factor in the human colonic adenoma-carcinoma sequence. Lab Invest 1996;75:25-32.
19. Terris B, Blaveri E, Crnogorac-Jurcevic T, et al. Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. Am J Pathol 2002;160:1745-54.
20. Emami S, Le Floch NN, Bruyneel E, et al. Induction of scattering and cellular invasion by trefoil peptides in src- and RhoA-transformed kidney and colonic epithelial cells. FASEB J 2001;15:351-61.
21. Rodrigues S, Nguyen QD, Faivre S, et al. Activation of cellular invasion by trefoil peptides and src is mediated by cyclooxygenase- and thromboxane A2 receptor-dependent signaling pathways. FASEB J 2001;15:1517-28.
22. Taupin DR, Kinoshita K, Podolsky DK. Intestinal trefoil factor confers colonic epithelial resistance to apoptosis. Proc Natl Acad Sci U S A 2000;97:799-804.
23. Rodrigues S, Van Aken E, Van Bocxlaer S, et al. Trefoil peptides as proangiogenic factors in vivo and in vitro: implication of cyclooxygenase-2 and EGF receptor signaling. FASEB J 2003;17:7-16.
24. Vestergaard EM, Poulsen SS, Grønbaek H, et al. Development and evaluation of an ELISA for human trefoil factor 3. Clin Chem 2002;48:1689-95.
25. Vestergaard EM, Brynskov J, Ejskjaer K, et al. Immunoassays of human trefoil factors 1 and 2: measured on serum from patients with inflammatory bowel disease. Scand J Clin Lab Invest 2004;64:146-56.
26. Solberg HE. Approved Recommendation on the Theory of Reference Values. Part 5. Statistical Treatment of Collected Values. Determination of Reference Limits. J Clin Chem Clin Biochem 1987;25:645-56.
27. Habbema JD, Eijkmans R, Krijnen P, et al. Analysis of the data on accuracy of diagnostic tests. In: Knottnerus JA, editor. The evidence base of clinical diagnosis. London: BMJ Books; 2002. p. 117-43.
28. Rhodes DR, Barrette TR, Rubin MA, Ghosh D, Chinnaiyan AM. Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res 2002;62:4427-33.